-
WELDING GmbH & Co. KG, through its business unit PHARMA FDF, announces its first European marketing authorizations for Tafamidis 61 mg soft capsules
WELDING GmbH & Co. KG announces an important regulatory milestone in Europe. Following the successful closure of the Decentralized Procedure (DCP) earlier this year, WELDING GmbH & Co. KG in collaboration with its partner Zenara Pharma Pvt Ltd has received its first marketing authorizations in Europe for Tafamidis 61 mg soft capsules. WELDING is among the first company in Europe to obtain multi country generic approval for this product, underlining the company’s regulatory expertise and its focus on enabling timely market access through structured and reliable development and registration pathways. This development further expands the company’s Finished Dosage Form (FDF) portfolio and reflects its focus on reliable, responsible, and sustainable partnership…
-
WELDING GmbH & Co. KG Expands to Latin America
WELDING GmbH & Co. KG announces the establishment of its Mexican subsidiary, WELDING Ingredientes SA de CV. With this step, our family-owned company is expanding its international presence and strengthening its position in the Latin American market. Our goal is to combine our long-standing European distribution expertise and global sourcing network with local market knowledge and a direct presence in Mexico. WELDING Ingredientes SA de CV has been established as an independent company and is headed by Managing Director Michael Kuhlmann. He brings 17 years of experience in the Mexican market, including 11 years in senior management positions. With his extensive knowledge of the local pharmaceutical and food industries, he…
-
Revio Therapeutics and Welding Group Announce Strategic Co-Development and Licensing Agreement for Innovative Specialty Oncology Product
Revio Therapeutics ("Revio") and Welding Group ("Welding") today announced the signing of a co-development and licensing agreement for Revio’s proprietary specialty oncology product. The 505(b)(2) product, designed based on an innovative dosage form with significant patient compliance and ease-of-use advantages, will be developed by Revio and commercialized by Welding through the partnership across the United States, Europe, and select global markets. A New Standard in Patient-Centric Oncology Care This collaboration combines Revio’s innovative 505(b)(2) drug development expertise with Welding’s commercial market access capabilities as well as therapeutic area expertise, positioning both organizations to address critical unmet needs in oncology patient care. Consistent with Revio’s business model of de-risking early, the program achieved a key milestone…
